CTEV News & Events

Claritev announced a strategic relationship with Kinetiq Health. The combined offering delivers monthly medical and pharmacy claims surveillance, risk stratification, and intervention support from clinical and financial experts. Clients also gain access to Kinetiq Health's Second Opinion Program.

The deal priced at midpoint of $50.00-$53.00 target range. Barclays, Guggenheim and Wells Fargo are acting as joint book running managers for the offering.